DTP budgets will rise above ’06 levels

Share this article:
Investment in patient education and patient-facing communications are on the rise, according to the results a newly released report from Cutting Edge Information.

The 263-page report—Patient Education and Direct-to-Patient Communication—compiles data from 20 different brand-based patient education programs from across the drug industry.
Among those surveyed, 76% revealed that their DTP budgets will increase from 2006 levels—not only in real dollars but also as a percentage of the overall marketing budget.

Surveyed marketing teams said they balance their brand plans with both DTC advertising and educational objectives, when necessary. Of the brands examined, five engaged in general DTC advertising, while twelve brands did not utilize DTC to achieve commercial goals.

Five of the eight brands that conducted DTC plan to maintain 2006’s DTC activity at the same level relative to patient education and other patient-focused communications, the report said.
Three of the surveyed brands plan to increase “the weight” of DTC advertising in their communications with end users. No brands plan to decrease DTC activity relative to patient education and other patient-focused communications.

One challenge for brand teams is determining how much of a promotional message to insert into their patient education material, the report said.

Surveyed brand team members favored branded material, at 43% of content, unbranded material 38%.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...